Pfizer (PFE) U.S. All Stars Conference summary

Strategic portfolio evolution and resource allocation

• Refocused on high-potential products and markets, reallocating resources from underperforming areas to key countries and products, resulting in significant operational efficiency gains.

• New and reacquired products grew from $0.5 billion in 2023 to $4 billion, while OpEx was cut and commercial execution improved.

• COVID franchise was scaled down from $11 billion in 2024 to a $4 billion guidance for 2026, with resources shifted to new growth platforms.

• Sales organization productivity tripled in three years through focused deployment and commercial model improvements.

• Commercial excellence and pipeline maturity underpin confidence in future growth, with 31 phase III studies ongoing.

Growth drivers and pipeline strategy

• New launches and acquired products form a $13 billion foundation, with strong growth in vaccines and oncology.

• Significant room for growth in adult and pediatric vaccines, with low current vaccination rates in major markets.

• Oncology pipeline targets high-impact tumor types, leveraging expertise and infrastructure in thoracic, breast, and prostate cancers.

• Chronic weight management and GLP-1 assets are positioned for a $120–$150 billion market by 2030, with a portfolio approach to address diverse patient needs.

• Portfolio management now emphasizes maximizing value across assets, using early signals and swing factors to guide capital allocation.

Global market dynamics and pricing

• Most Favored Nation (MFN) agreements reduced tariff risks and prompted moves toward price parity between the U.S. and international markets.

• Governments in the UK and Japan are showing willingness to support higher prices for innovation, with policy changes to improve patent protection and reimbursement.

• The rise of China as a biotech powerhouse is reshaping the innovation landscape, with 50% of global clinical studies in key oncology platforms now run in China.

• Partnerships and competition with Chinese firms are intensifying, prompting investments in AI and commercial capabilities to maintain competitiveness.